DBTX News and Press, Decibel Therapeutics Inc. From 08/09/23

2023-08-09 10:08:11 ET Gainers: Tango Therapeutics ( TNGX ) +137% . Decibel Therapeutics ( DBTX ) +72% . Mirati Therapeutics ( MRTX ) +26% . Azenta ( AZTA ) +25% . Clover Health Investments ( CLOV ) +18 % . Losers: ...

MONSEY, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right (“CVR”) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc. (Nasdaq: DBTX) ...

2023-08-09 08:06:59 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) has agreed to acquire Decibel Therapeutics ( DBTX ), a micro-cap biotech focused on developing gene therapies for hearing disorders, for $4.00 per share in cash plus a contingent value right, the companies announc...

Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related ...

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, w...

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clini...

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, wi...

- Initiated CHORD™ , a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two year...

2023-05-12 07:58:17 ET Decibel Therapeutics' ( NASDAQ: DBTX ) application to start a trial of its  gene therapy DB-OTO to treat children with a type of hearing loss was approved in Spain. Spanish Agency of Medicines and Medical Devices approved the clinical trial app...

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application (CTA) by th...